Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Goldman Sachs Starts Atara Biotherapeutics (ATRA) at Neutral
November 10, 2014 7:20 AM ESTGoldman Sachs initiated coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Neutral rating and a price target of $30.00.
Analyst Navdeep Singh said, "Atara is an early-stage biotech developing (1) PINTA 745 for kidney dialysis patients who suffer from muscle wasting and (2) STM 434 for advanced ovarian... More
Jefferies Starts Atara Biotherapeutics (ATRA) at Buy
November 10, 2014 7:13 AM ESTJefferies initiates coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Buy rating and a price target of $35.00.
Analyst Ryan Martins states, "ATRA has a proven management team with extensive experience in licensing and developing products. We believe ATRA's two lead clinical products, PINTA 745 and STM 434,... More
